LGND – ligand pharmaceuticals incorporated (US:NASDAQ)
Stock Stats
News
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $150.00 to $160.00. They now have an "overweight" rating on the stock.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Royal Bank of Canada from $141.00 to $143.00. They now have an "outperform" rating on the stock.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance [Yahoo! Finance]
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
Form 4 LIGAND PHARMACEUTICALS For: Dec 05 Filed by: Espinoza Octavio
Form 4 LIGAND PHARMACEUTICALS For: Nov 27 Filed by: LAMATTINA JOHN L
Form 144 LIGAND PHARMACEUTICALS Filed by: LAMATTINA JOHN L
Form SC 13G/A LIGAND PHARMACEUTICALS Filed by: JANUS HENDERSON GROUP PLC
Form 144 LIGAND PHARMACEUTICALS Filed by: Korenberg Matthew E
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.